Association Of Therapeutic Management With A Good Prognosis In Unresectable Hepatocellular Carcinoma Patients Undergoing Sorafenib Treatment: Dose Adjustment And Conversion Therapy.

498Background: When treating hepatocellular carcinoma (HCC) with sorafenib, it is important for the physician to evaluate the therapeutic effects because of the characteristic therapeutic response, the toxicity, and out of consideration for the liver function. We evaluated the relationship between changes in therapeutic management and the efficacy of sorafenib in the treatment of unresectable HCC. Methods: Out of a total of 118 patients who received sorafenib in our hospital between January 2010 and September 2017, 96 patients could be followed up and were included in the present study. We evaluated the profile of sorafenib treatment (etiology, cStage, initial dose, the percentage of cases in which the dose was changed), the clinical response by mRECIST, adverse events by CTCAE v.4.0, overall survival (OS), and the rate of patients continued sorafenib treatment or underwent conversion therapy after the development of progressive disease (PD) in two distinct periods of treatment: the former period (in whic...